Trandate · DIN 02106280 · 200 mg · tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Trandate · DIN 02106280
Manufacturer: Knight Therapeutics Inc.; listing date 1998-03-17
Health Canada: Marketed since 2025-12-29 · brand TRANDATE · ATC C07AG01 LABETALOL · form Tablet · route Oral · ingredients LABETALOL HYDROCHLORIDE 200 MG · company Knight therapeutics inc. · schedule Prescription
Ministry pays: $0.3504 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02106280)
Source record
DIN 02106280: Trandate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800094; group id 332; item number 0744; lccId None; manufacturer id KNT
Source form: Tab; strength: 200mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.7148; ministry $0.3504
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02106280
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=29543
Interchangeable products
Apo-Labetalol · DIN 02243539 · $0.3504
Riva-Labetalol · DIN 02489414 · $0.3504
Shortage status: not checked (no credentials)